Compare Domino's Pizza, Inc. (DPZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Novavax Inc — how do they compare? Domino's Pizza, Inc. trades at $309.36 (market cap $10.21B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Domino's Pizza, Inc. is far larger — about 5.6× Novavax Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Novavax Inc for 59 Days on average.
| DPZ | NVAX | |
|---|---|---|
Market Cap | $10.21B | $1.82B |
Volume | 916,737 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $12.56 |
52-Week Low | $282.89 | $6.22 |
Typical Hold Time | 106 Days | 59 Days |
Enterprise Value | $15.17B | $1.39B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $308.65, up 1.83% today, with a bullish technical signal but recent earnings misses. Revenue grew to $4.94B in 2025 with a net income margin of 11.86%, though the company carries significant debt. Analyst consensus is a Buy with a $373 price target, but news highlights concerns over dividend growth and store closures.
The outlook is mixed: strong profitability and analyst support suggest upside, but high debt and recent underperformance pose risks. Investors should weigh solid fundamentals against execution challenges and macroeconomic pressures on the restaurant sector.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
